Pharmgate Animal Health announced that its Deracin generic brand of chlortetracycline has been approved by the Food & Drug Administration for use in combination with the antimicrobial Denagard (tiamulin hydrogen fumarate) for swine.

The combination is approved for the treatment of swine dysentery, enteritis and pneumonia, Pharmgate said.

“The new combination of Deracin and Denagard provides an economical, easy-to-use tool to treat sick pigs,” said Colin Gray, president and chief executive officer of Pharmgate Animal Health. “Deracin gives producers and swine veterinarians a choice in chlortetracycline without the need to change treatment protocols or question how it will work.”

Deracin is a broad-spectrum medicated feed article (MFA) that is effective against Gram-positive and Gram-negative organisms that cause diseases such as enteritis, pneumonia, ileitis, leptospirosis and jowl abscesses, Pharmgate said. Deracin is readily absorbed via oral administration, so it quickly reaches effective blood and lung concentrations.

It is a veterinary feed directive (VFD) drug to be used by or on the order of a licensed veterinarian.

Pharmgate said its pioneer chlortetracycline product, Pennchlor, continues to be approved for combination use with Denagard. Like Deracin, Pennchlor is a broad-spectrum MFA and effective against Gram-positive and Gram-negative organisms. Pennchlor is highly concentrated for reduced handling and delivers versatility with a wide range of approved combinations, Pharmgate added.

“Our diverse product portfolio demonstrates our ongoing commitment to provide the industry useful, effective, high-quality products,” Gray said. “Offering both products provides producers, veterinarians and feed mills chlortetracycline treatment options.”

Pharmgate Animal Health is headquartered in Wilmington, N.C., and provides innovative and high-quality products that help the livestock industry optimize animal health, efficiency and production. The company’s pharmaceutical production facilities are located in Omaha, Neb.; vaccine research and manufacturing operations are based in St. Paul, Minn.